🇬🇧·4d agoIndustry
23 March 2026GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in JapanDesignation supported by early clinical data showing durable responses in certain types of small-cell lung cancer (SCLC).
Publisher
G
GSK RSS
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on gsk.com
Leave the platform to read the original full article on the publisher site.
Source: GSK RSS
Scope: Industry
Related coverage